Shares of Nuvation Bio Inc. (NUVB), which transitioned to a commercial-stage company in 2025, trade around $5, approximately 49% below their 52-week high of $9.75 reached last December.
The company's lead product, IBTROZI, indicated for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer, received regulatory approval in China in January 2025, followed by U.S. FDA approval in June 2025 and approval in Japan in September 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com